Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Entewell-0.5 Entecavir Tablets, 0.5 mg
Entewell-0.5, provided by Lexaro Healthcare, contains 0.5 mg of Entecavir in each tablet. This formulation is designed to provide effective treatment for chronic hepatitis B virus (HBV) infection, helping to manage and control the viral load in affected patients.
Uses of Entewell-0.5 Entecavir Tablets, 0.5 mg
Entewell-0.5 is primarily prescribed for the treatment of chronic hepatitis B virus (HBV) infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.
Benefits of Entewell-0.5 Entecavir Tablets, 0.5 mg
Provides effective treatment for chronic hepatitis B virus (HBV) infection.
Helps to reduce the viral load in the body.
Improves liver function and reduces liver inflammation.
Delays the progression of liver disease.
Convenient once-daily dosing for improved patient compliance.
Well-tolerated with a favorable safety profile when used as directed.
Mechanism of Action of Entewell-0.5 Entecavir Tablets, 0.5 mg
Entecavir is a nucleoside analogue that works by inhibiting the reverse transcriptase enzyme of the hepatitis B virus (HBV). This inhibition prevents the replication of viral DNA, thereby reducing the amount of virus in the blood. Entecavir has a high barrier to resistance and is effective in both treatment-naive and treatment-experienced patients. By reducing viral replication, Entewell-0.5 helps to manage the infection, improve liver function, and delay the progression of liver disease.
Beside this well also export in other countries